0001209191-18-022389.txt : 20180402
0001209191-18-022389.hdr.sgml : 20180402
20180402163655
ACCESSION NUMBER: 0001209191-18-022389
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180322
FILED AS OF DATE: 20180402
DATE AS OF CHANGE: 20180402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LUDLAM WILLIAM
CENTRAL INDEX KEY: 0001736280
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37500
FILM NUMBER: 18729414
MAIL ADDRESS:
STREET 1: C/O CHIASMA, INC.
STREET 2: 460 TOTTEN POND ROAD, SUITE 530
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHIASMA, INC
CENTRAL INDEX KEY: 0001339469
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 460 TOTTEN POND ROAD
STREET 2: SUITE 530
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-928-5300
MAIL ADDRESS:
STREET 1: 460 TOTTEN POND ROAD
STREET 2: SUITE 530
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: CHIASMA INC
DATE OF NAME CHANGE: 20050922
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2018-03-22
0
0001339469
CHIASMA, INC
CHMA
0001736280
LUDLAM WILLIAM
C/O CHIASMA, INC.
460 TOTTEN POND ROAD SUITE 530
WALTHAM
MA
02451
0
1
0
0
See Remarks
Common Stock
5124
D
Stock Option (Right to Buy)
28.40
2025-09-10
Common Stock
14084
D
Stock Option (Right to Buy)
28.40
2025-09-10
Common Stock
45916
D
Stock Option (Right to Buy)
9.93
2026-02-10
Common Stock
969
D
Stock Option (Right to Buy)
9.93
2026-02-10
Common Stock
14531
D
Stock Option (Right to Buy)
2.60
2026-10-25
Common Stock
25003
D
Stock Option (Right to Buy)
2.60
2026-10-25
Common Stock
74997
D
Stock Option (Right to Buy)
1.52
2028-02-23
Common Stock
52011
D
Stock Option (Right to Buy)
1.52
2028-02-23
Common Stock
18189
D
This option vests over a four-year period at a rate of twenty-five percent (25%) on August 26, 2016 and 36 equal monthly installments thereafter.
This option vests over a four-year period at a rate of twenty-five percent (25%) on February 10, 2017 and in 12 equal quarterly installments thereafter.
This option vests over a four-year period at a rate of twenty-five percent (25%) on October 25, 2017 and in 12 equal quarterly installments thereafter.
This option vests over a four-year period in 16 equal quarterly installments, the first such installment vesting on May 23, 2018.
This option vests as follows: (i) 40% of such award will be earned upon FDA acceptance of a new drug application ("NDA") for Mycapssa, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such acceptance; and (ii) 60% of such award will be earned upon FDA approval of such NDA, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such approval.
Title: Senior Vice President, Clinical and Medical Affairs
/s/ William Ludlam
2018-04-02